We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA: Purdue’s Avridi Raises Questions About Opioid Use on Empty Stomach
FDA: Purdue’s Avridi Raises Questions About Opioid Use on Empty Stomach
The FDA is concerned that patients will have trouble complying with instructions for Purdue Pharma’s oxycodone drug Avridi, as two advisory panels prepare to discuss the effect of food intake on the abuse-deterrent opioid.